Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 8

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
 adjustment  258,270   (115,379)NET CHANGE IN CASH AND CASH EQUIVALENTS  (1,349,777)  (555,503)CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL PERIOD  2,886,966   4,517,710          CASH AND CASH EQUIVALENTS, END OF FINANCIAL PERIOD $1,537,189  $3,962,207          CASH AND CASH EQUIVALENTS INFORMATION:        Fixed deposits placed with financial institutions with original maturities of three months or less $723,010  $1,762,360 Cash and bank balances  814,179   2,199,847 Cash and cash equivalents, end of financial period  1,537,189   3,962,207          Supplementary cash flow information:        Interest paid $(3,168) $(4,546)Income tax paid  (12,514)  (26,772)

See accompanying notes to the condensed consolidated financial statements.

 8Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all the outstanding capital stock of Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation (“BioNexus Malaysia”). BioNexus Malaysia was incorporated in Malaysia on April 7, 2015 and subsequently changed its name to MRNA Scientific Sdn. Bhd. (“MRNA Scientific”) on September 19, 2023. The principal office address is Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No.5 Jalan Bangsar Utama 1, Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang